Series C Funding Accelerates Nourish Metabolic Care Expansion
Nourish raised $100M in its Series C round which will be used to accelerate its expansion of AI driven metabolic health clinics throughout the US. The funding round was led by Menlo Ventures and included other key investors like Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures and Y Combinator.
Nourish is currently the leading dietitian-led metabolic health clinic in the U.S and is a model that combines the use of nutritional care, medical care, and technology to assist in long term behavioral changes and solving chronic illness.
Nourish already serves all 50 states, and their partnerships with insurance providers let them reach over 200 million people—most of whom are covered by insurance. This fresh investment brings Nourish’s valuation up to $1.75 billion.
AI-Native Clinical Model Targets Chronic Disease Crisis
Nourish is focused on treating nutrition-related chronic diseases at scale. Nearly 200 million Americans live with conditions linked to metabolic health. These conditions drive a significant share of US healthcare spending. They also contribute to more than one million preventable deaths each year.
The company delivers care through registered dietitians supported by AI systems. Each patient receives a personalised care plan. This includes nutrition guidance, lab testing, and medical support when required. The model integrates GLP-1 prescribing where clinically appropriate.
CEO Aidan Dewar said the US healthcare system is not designed to treat chronic disease effectively. He noted that care is often fragmented and reactive. Nourish aims to replace this with continuous, coordinated metabolic care.
The company reports strong clinical outcomes from its model. Patients achieve an average 8 percent weight loss. They also show improvements in A1C, LDL cholesterol, and blood pressure. These results translate into more than $2,000 in annual cost savings per patient for health plans.
Nourish also integrates GLP-1 medication management into its care model. The company emphasises that medication alone is not sufficient. Many patients discontinue treatment within six months. Without ongoing support, weight regain is common.
Investor Confidence Driven by Clinical Outcomes and Scale
Institutional investment accelerates AI-driven metabolic care, expanding clinical networks and scalable chronic disease management across healthcare systems. Source: Created by Ventureburn
Menlo Ventures led the Series C round. Partner J.P. Sanday is joining the company’s board. He said chronic disease represents one of the largest failures in healthcare. He also highlighted Nourish’s ability to improve both outcomes and cost efficiency.
Other investors in the round include Thrive Capital, Index Ventures, and JPMorgan Chase’s growth equity arm. The participation reflects strong institutional confidence in digital health platforms. It also signals growing interest in scalable chronic disease solutions.
Investors noted the company’s rapid growth and strong adoption across healthcare systems. Nourish has scaled to over 10,000 registered dietitians. It has also completed millions of patient appointments since launch.
The company has also built strong referral networks. More than 250 health systems actively refer patients into its platform. These partnerships support widespread access to metabolic care services.
More News: Hellbender Secures $12.5M to Scale Physical AI Edge Infrastructure
Expansion Strategy Focused on AI Agents and Care Integration
Nourish plans to expand its AI agent infrastructure across its platform. Patients already interact with AI health agents through a mobile application. These tools support behaviour change and improve engagement over time.
The company also uses AI copilot systems for providers. These tools take some of the administrative burden off clinicians and quickly highlight important clinical information, which improves both the quality and efficiency of care throughout the network.
Nourish is expanding its integrated care model, too. Patients get coordinated support from dietitians, doctors, and digital platforms all working together. That kind of teamwork keeps care consistent at every step.
CEO Aidan Dewar pointed out that more people are seeking metabolic care these days. He said that pairing GLP-1 medications with nutrition support is changing the way people approach treatment. Nourish’s goal is to create a system that helps patients achieve better long-term results.
The company is hiring across clinical and operational roles. It is also expanding partnerships with employers and health systems. These efforts are designed to support national-scale access to metabolic health care.
To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.
